Show pageBacklinksCite current pageExport to PDFBack to top This page is read only. You can view the source, but not change it. Ask your administrator if you think this is wrong. Patients with [[leptomeningeal carcinomatosis]] face a particularly grim prognosis. Current treatment consists of [[intrathecal]] delivery of [[methotrexate]] (MTX) or [[cytosine arabinoside]] (Ara-C) via [[ventricular access device]] ([[Ommaya reservoir]]) or [[lumbar puncture]]. Yet despite these interventions, the median survival after diagnosis is only 4-7 months ((Chen TC, Napolitano GR, Adell F, Schönthal AH, Shachar Y. Development of the Metronomic Biofeedback Pump for leptomeningeal carcinomatosis: technical note. J Neurosurg. 2015 Aug;123(2):362-72. doi: 10.3171/2014.10.JNS14343. Epub 2015 May 8. PubMed PMID: 25955873. )). cytosine_arabinoside.txt Last modified: 2024/06/07 02:56by 127.0.0.1